Share This

Wednesday, 9 March 2011

St Jude Hi-tech medical boost for Penang




Starks: The new facility uses environmentally beneficial technologies.  

By DAVID TAN davidtan@thestar.com.my

Hi-tech medical boost for Penang

 Simulation centre to train docs from Asia Pacific

PENANG will serve as a hub to train physicians from the Asia Pacific region on new medical technologies next year when the Advanced Technology Centre at St Jude Medical Inc facility in Bayan Lepas starts operations.

Chief Minister Lim Guan Eng said the centre would be equipped with a wet laboratory and state-of-the-art computers that could provide simulation of the human anatomy system to train the physicians.

He said the funding for the centre would come from the US$300mil planned by St Jude Medical for the 300,000sq ft facility in Penang.

According to a Global Business Intelligence research report, the global cardiovascular market was expected to hit US$415bil in 2016, driven by the increase of cardiovascular diseases, Lim added.

“Equipped with the CE Mark approval certification, St Jude Medical has started shipping out its pacemakers and other devices to the company’s distribution centre in Sweden,” he told a press conference after opening St Jude Medical’s new facility at the Bayan Lepas Free Industrial Zone yesterday.

Lim said the company planned to invest more than US$300mil into the Penang plant over the next five years to be used for infrastructure, wages, and capital.


He said the plant, which was now employing 150 workers, was expected to create about 2,000 jobs in the next five years.

St Jude Medical chairman Daniel Starks said the new facility incorporated environmentally beneficial technologies.

“One such environmentally friendly feature is a rain harvesting system which will use ‘grey water’ to water plants.

“This will save about 200,000 gallons of city water annually based on occupation of the building,” he added.

Headquartered in Minnesota, St Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide.

Its products include implantable cardioverter defibrillators (ICDs), cardiac resynchronisation therapy (CRT) devices, pace-makers, electrophysiology catheters, mapping and visualisation systems, vascular closure devices, heart valve replacement and repair products, spinal cord stimulation and deep brain stimulation devices.

 St Jude Medical to invest US$300mil in Penang facility

GEORGE TOWN: St Jude Medical Inc plans to spend US$300mil on its new manufacturing facility in Penang over the next five years.

St Jude Medical chairman and president Daniel Starks said the investment would be for infrastructure, capital and wages in Penang, which would create about 2,000 jobs.

He was speaking after the launching of the new plant in Bayan Lepas by Penang Chief Minister Lim Guan Eng,

Starks said the investment would include the funding for an advanced technology centre, which was expected to be operational next year.

The company had invested about US$67mil in the manufacturing facility.

“The centre will bring in physicians from Asia Pacific and train them on the latest development in medical technology from St Jude Medical.

“The centre would use virtual reality technology to train the physicians,” he said.

Starks added that the Penang manufacturing facility would initially produce products for the company's cardiac rhythm management division.



“The CE mark approval, the required endorsement for selling products in Europe, for the manufacture of pacemakers and leads, was awarded in January and the first Accent pacemakers made in Malaysia have already been provided to physicians.

“In addition to pacemakers and leads, St Jude Medical plans to expand production to include additional products such as implantable cardioverter defibrillators (ICDs) over the next several years,” he said.

Headquartered in Minnesota, St Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide.

Its products include ICDs, cardiac resynchronisation therapy devices, pacemakers, electrophysiology catheters, mapping and visualisation systems, etc.

The company reported net sales of US$1.3bil in the fourth quarter of 2010 ended Jan 1, 2011, an increase of 12% over the US$1.2bil in the fourth quarter of 2009. Net sales in 2010 were US$5.165bil compared with US$4.681bil in 2009, an increase of 10%.

No comments:

Post a Comment